Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose‐limiting toxicity (DLT) in colon can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Ali, Raafi, Baracos, Vickie E., Sawyer, Michael B., Bianchi, Laurent, Roberts, Sarah, Assenat, Eric, Mollevi, Caroline, Senesse, Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4831278/
https://ncbi.nlm.nih.gov/pubmed/26814378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.621
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados